Moderna & Merck Achieve Milestone in Cancer Treatment

Moderna and Merck's individualized mRNA therapy for melanoma has achieved positive Phase 3 results, marking the first time a cancer vaccine trial has demonstrated such success. This breakthrough comes after more than 20 years and over 1,000 failed trials in cancer vaccine research. The treatment, which is an individualized therapy combined with Keytruda, met its primary endpoint for recurrence-free survival, offering a new approach to combat this aggressive cancer.

The clinical trial further exceeded expectations by meeting its secondary endpoint of distant metastasis-free survival during an unexpected interim analysis. This positive outcome reinforces the therapy's clinical efficacy beyond just preventing local recurrence. Achieving distant metastasis-free survival is a critical indicator, suggesting the treatment's ability to prevent cancer from spreading to other parts of the body, which is crucial for long-term patient outcomes.

The Phase 2 data from the trial showed a significant improvement in recurrence-free survival, with approximately 50% of patients achieving this compared to those receiving Keytruda alone. Furthermore, 80% of patients were disease-free five years after surgery and treatment. In oncology, a five-year disease-free survival rate is often medically considered equivalent to a cure, highlighting the profound potential of this new therapy.

Moderna is actively engaging with regulatory bodies to file for approval, with the goal of making the drug available to patients as soon as 2027. The company's manufacturing facility in Massachusetts is already prepared for scaling production to meet anticipated demand. This proactive approach aims to ensure that personalized mRNA cancer treatment can be made scalable and accessible to every patient who needs it once approved.

Current checkpoint inhibitors like Keytruda demonstrate about 60% efficacy in treating cancer, leaving a significant 40% of patients who do not respond to the standard treatment. These non-responders face continued struggle against their cancer, often enduring treatments that ultimately prove ineffective. Furthermore, existing immunotherapies can lead to severe side effects, including autoimmune diseases such as Type 1 diabetes and lupus, highlighting the need for more targeted and less toxic alternatives.

Moderna partnered with Merck in 2015-2016 to develop a therapeutic mechanism that is entirely orthogonal, or distinct, from existing immunotherapies. The collaboration aimed to leverage Moderna's mRNA technology to create a more precise immune response by starting with the sequence of a patient's tumor. This strategy built upon lessons learned from Moderna's infectious disease vaccine programs, adapting them to the complexities of cancer treatment.

Traditional immunotherapy treatments, such as Keytruda, are described as 'unleashing the dogs' of the immune system, but this activation can be somewhat random, sometimes targeting healthy cells. In contrast, Moderna's mRNA technology offers molecular-level precision, specifically teaching T-cells within the immune system what exact markers to look for on cancer cells. This targeted approach aims to direct the immune response with greater accuracy, preventing the indiscriminate attack on the body's own tissues.

While traditional vaccines aim to prevent disease, cancer vaccines like Moderna's new therapy serve a therapeutic purpose: to prevent the recurrence of cancer. The term 'vaccine' is still applicable because the underlying mechanism involves teaching the immune system to recognize and respond to specific threats. The goal is to alert the immune system to cancer signals that it previously ignored, thereby preventing the disease from returning.

Over 1,000 previous clinical trials for cancer vaccines failed before Moderna and Merck's recent success. This breakthrough is largely attributed to advancements in mRNA technology and the patient-specific design of the new treatment. Previous attempts often relied on injecting proteins or peptides, which did not effectively present antigens 'from within' the cells, leading to insufficient immune responses. Moderna's approach, however, delivers mRNA directly to antigen-presenting cells in the lymph nodes, enabling the body to produce the necessary antigens internally, similar to how COVID and flu shots work.

The development of personalized mRNA cancer vaccines involves a meticulous process of genomic comparison. Due to significant reductions in sequencing costs over the past two decades, a biopsy of the patient's tumor is taken, and its entire DNA (approximately 3 gigabytes) is sequenced. Simultaneously, the DNA from the patient's healthy cells is also sequenced. These two genomic profiles are then compared letter by letter, nucleotide by nucleotide, to identify unique mutations present only in the tumor. Advanced algorithms are subsequently used to pinpoint the most relevant mutations that the immune system needs to recognize to effectively target the cancer.

Moderna's proprietary algorithm, referred to as 'Version 1.0,' is the result of over 10 years of development, integrating a wealth of data to identify optimal cancer targets. This algorithm began by incorporating established knowledge in the field, drawing from numerous public databases, scientific publications, and insights from leading immunologists and oncologists. Building on this foundation, Moderna has generated and utilized extensive internal data, including T-cell mapping, to refine its selection criteria for mutations. This core algorithm has remained consistent throughout the Phase 1, 2, and 3 clinical trials, underscoring its robustness and reliability in personalized vaccine design.

Stéphane Bancel, Moderna's CEO, views the current version of mRNA cancer therapy as merely the 'worst version' that will ever exist in medical history. This perspective underscores his strong belief in the vast potential for future advancements and continuous improvement of the technology. The innovative approach is already being considered for notoriously difficult-to-treat cancers, such as pancreatic cancer, where current therapies offer limited success. Moderna anticipates that ongoing research and continuous learning from clinical results will drive future iterations, leading to increasingly effective treatments for a broader range of cancers, marking the beginning of a long-term trajectory of medical progress.

Industrialized production of mRNA therapies significantly reduces the risks associated with contamination and quality control inherent in manual processes. Stéphane Bancel highlights that making an injectable product manually carries a substantial risk of bacterial contamination; even a single bacterium injected into a patient could lead to sepsis. Furthermore, multi-step manual production processes increase the likelihood of human error, compromising product quality. Industrialized facilities, however, adhere to stringent FDA Good Manufacturing Practice standards, ensuring a sterile and consistent output, which is crucial for patient safety.

A core challenge in the clinical validation of personalized cancer vaccines is ensuring the consistency of the final product for each individual patient. Regulatory bodies, particularly the FDA, require robust demonstration that the manufacturing process reliably produces the same product when starting with identical biological samples. This involves proving that the complex 'black box' system, which converts tumor and blood samples into a personalized vaccine, consistently generates the intended therapeutic output. Discussions with regulators regarding these validation standards have been ongoing for more than a decade, underscoring the novelty and complexity of this individualized treatment approach.

Moderna plans to expand its cancer therapy into various cancer types, particularly those where PD-1 inhibitors like Keytruda are already effective, due to the orthogonal nature of their mRNA mechanism. Phase 3 studies are currently active for lung cancer, with Phase 2 studies underway for kidney and bladder cancers. The strategy also includes targeting earlier disease stages as a monotherapy to potentially avoid the systemic side effects associated with checkpoint inhibitors, offering a less burdensome treatment option for patients.

Moderna envisions using its mRNA technology as a monotherapy for early-stage cancers, such as stage one lung cancer, which can be detected through regular screenings like X-rays. This approach would allow patients to avoid systemic checkpoint inhibitors and their associated lifelong autoimmune side effects. The proposed monotherapy would have side effects similar to a typical vaccine, like a day of tiredness, making it a much more tolerable option. This strategy emphasizes the importance of regular screening for high-risk populations, such as former smokers, to detect cancer at its earliest, most treatable stages.

Moderna is intensely focused on understanding why 20% of patients do not respond to their cancer therapy even five years out. To address this, they are leveraging AI to analyze massive clinical datasets, aiming to identify patterns and insights from non-responders. The goal is to refine their mRNA 1.0 algorithm and technology based on these data-driven insights. By pinpointing what might be missing or incorrect in the current approach for these patients, Moderna hopes to iterate and improve the therapy, ultimately increasing response rates and helping a broader range of individuals.

Moderna is exploring novel approaches to treat the root causes of autoimmune diseases, moving beyond the symptom management prevalent in the pharmaceutical industry. The company believes it may have found ways to harness the immune system itself to address the underlying mechanisms of these conditions. This involves developing both standardized products and individualized treatments designed to target specific immune cells that mistakenly identify the body's own tissues as threats. By retraining these immune cells, Moderna aims to provide more lasting and fundamental solutions for autoimmune disorders.